Is this stock ever going lift off in major way?
Tired of these sluggish movements
This is my first biotech buy (around 15 average) in 2 years because I was not seeing any good values. Most biotech stock are at decade high on valuation scale.
ACHN is a diamond in the rough,
WS crooks playing this 51.5 wall like a ping-pong.
Market is thru the roof, AAL estimates thru the roof, oil down so why is the problem with 5-10% up day?
6X forward estimates. Are you kidding me? Are we in recession?
the whole WS (big institutions + analysts) is a big racket that should have been cleaned up years ago.
Now that is balanced article. Thanks for sharing
My personal take is that analysts (for whatever motives) are putting negative spin on this based on 3422 which did not have spectacular results, while completely ignoring 3102+Sovaldi. That combination reported even more spectacular results than what they reported in November.
dont know. but i read AF article like 10 times and came out as misleading article. His conclusions dont make sense at all
1. GILD dominance is totally broken by ABBV/express. GILD is now a desperate hungry lion eager to regain its dominance. GILD has another potential threat from Merck
2. ACHN has at least 1 regimen (3102+Sovaldi) that is better than Sovaldi alone and has potential to displace Sovaldi alone regimen. GILD will be totally stupid to let ACHN go with 3102 on their own. With ACHN drugs, GILD can have multi-tier pricing structure with the most potent drug combination costing the most
3. Merck and ABBV can literally throw billions to prevent GILD from gaining dominance in HCV
4. ACHN is the only small cap biotech that has clearly demonstrated huge potential.
5. You get the idea...
Expect GILD to become more and more desperate
3102+sovaldi and 3422+3102 will be potent combinations going forward.
A company that has most drugs will be able to go to more trials than others.
Algos were most likely programmed to sell biotechs today. ACHN being a small cap and in the same space as GILD got whacked worst.
There was a relentless, senseless computer driven trading with no regard to fundamentals.
WHO estimates that about 3% of the world's population has been infected with HCV and that there are more than 170 million chronic carriers who are at risk of developing liver cirrhosis and/or liver cancer.
= 750 billion potential spend on treatment
according to following SA article
If you assume that only 10% of this market materializes = 75 billion market opportunity.
If you assume that ACHN being a small players only takes up 10% of the market = 7.5 billion potential opportunity for ACHN alone.
Remember, GILD and ABBV two of the biggest players are already 100+ billion market cap companies.
A large successful ph 2/3 trial will take ACHN valuation into several billions. Whether GILD wants to play that game or not remains to be seen.
GILD is 130 billion company with 1/2 of revenue from HepC market